

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Kerschberger, B; Boulle, AM; Kranzer, K; Hilderbrand, K; Schomaker, M; Coetzee, D; Goemaere, E; Van Cutsem, G; (2015) Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy. *Journal of the International AIDS Society*, 18 (1). p. 20092. ISSN 1758-2652 DOI: <https://doi.org/10.7448/IAS.18.1.20092>

Downloaded from: <http://researchonline.lshtm.ac.uk/2312419/>

DOI: <https://doi.org/10.7448/IAS.18.1.20092>

Usage Guidelines:

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by/2.5/>

<https://researchonline.lshtm.ac.uk>

1 **Additional file 1. Unadjusted and adjusted hazard ratios of virologic failure (n=**
 2 **6264).**

3

	Univariate analysis			Multivariate analysis		
	cHR*	95% CI	p	aHR**	95% CI	p
VL group						
6 months	1		0.257	1		0.016
3 months	1.10	0.93-1.29		0.78	0.64-0.95	
Sex						
Female	1		0.058	1		0.767
Male	0.84	0.70-1.01		0.97	0.80-1.18	
Age¹	0.71	0.63-0.79	<0.001	0.72	0.64-0.81	<0.001
CD4 count²	0.90	0.85-0.95	<0.001	0.91	0.85-0.96	0.001
WHO stage						
I + II	1		0.001	1		0.001
III + IV	1.50	1.19-1.89		1.57	1.21-2.03	
Clinic						
I	1		0.28	1		0.437
II	0.96	0.78-1.19		0.92	0.73-1.14	
III	1.12	0.93-1.34		1.08	0.90-1.30	
Baseline NNRTI						
Nevirapine	1		0.004	1		<0.001
Efavirenz	0.79	0.68-0.93		0.73	0.61-0.87	
ART initiation³						
	0.97	0.95-0.98	<0.001	0.97	0.95-0.98	<0.001

4

5 * cHR, crude hazard ratio

6 ** aHR, adjusted hazard ratio

7 *** PHA, p value for the global proportional-hazards assumption; VIF, range of

8 variance inflation factors

9 ¹ per 10 years

10 ² per 50 cells/ μ l

11 ³ Calendar time of ART initiation; per 90 days